Clinical Trials | December 30, 2025
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
The study met its primary endpoint with flying colors
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
